Adjunctive use of xanomeline/trospium chloride (Cobenfy) offered no statistically ... The US Food and Drug Administration (FDA) approved xanomeline/trospium for schizophrenia in September last ...

Cobenfy, already approved to treat schizophrenia ... The trial would have supported a broader approval for the drug.

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

While the Cobenfy stumble and another recent setback for Bristol’s cardiomyopathy drug Camzyos were “not the results we had hoped for,” there is a need to “put the results in proper ...

The Phase 3 test evaluated the drug, Cobenfy, as an adjunct to atypical antipsychotics in adults whose schizophrenia symptoms were inadequately controlled by these standard-of-care drugs.

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed.

Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in $27 million in net sales in the first three months of the year — beating Wall Street sales expectations and analyst predictions.

In September 2024, the FDA approved Cobenfy, an oral medication for schizophrenia in adults. Data from the EMERGENT clinical program supported the FDA approval of Cobenfy. In Phase 3 EMERGENT-2 ...

The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades.

We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb’s schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal, and more.

A brain drug at the center of a recent $14 billion ... with about half taking Cobenfy and the other half a placebo. Using a well-known, 210-point scale that measures the severity of schizophrenia ...